Skip to content

Comparison Between Letrozole and Mifepristone in Medical Termination of First Trimester Miscarriages

COMPARATIVE STUDY OF EFFECTS BETWEEN LETROZOLE PLUS MISOPROSTOL AND MIFEPRISTONE PLUS MISOPROSTOL IN TERMINATING NON-VIABLE FIRST TRIMESTER PREGNANCIES

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05304273
Enrollment
120
Registered
2022-03-31
Start date
2022-05-05
Completion date
2024-10-01
Last updated
2026-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Miscarriage

Brief summary

Prospective interventional study where participants with non-viable pregnancy at 1st trimester will be randomized into two arms, one group will receive conventional treatment with oral mifepristone followed by misoprostol vaginally and another group will receive letrozole for three consecutive days followed by misoprostol vaginally in an attempt to terminate the pregnancy medically. Mean duration of induction to expulsion of product of conception and rate of complete abortion will be compared in two groups.

Interventions

DRUGMifepristone

Participants with 1st trimester miscarriage will receive for medical termination

DRUGLetrozole

Participants with 1st trimester miscarriage will receive for medical termination

Sponsors

Calcutta National Medical College and Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

: * Women older than 18years who will give consent regarding medical management of missed abortion * First trimester pregnancy (gestational age less than equal to 12weeks) with missed abortion confirmed by ultrasonography * Hemoglobin level more than 12g/dl. To improve sample size later hemoglobin level 10 gm% or more was considered and EC was informed on 5.10.2022 about this minor change in the study design.

Exclusion criteria

: * Hemodynamically unstable patient * Abnormalities in blood tests including complete blood count (CBC), prothrombin time(PT), internationalised normalized ratio(INR) and fibrinogen * History or clinical evidence of any thromboembolic impairment or deep venous thrombosis * Having intra-uterine device * Present or previous use of corticosteroids * History of any malignancy * Existing cardiovascular disease contraindicating misoprostol

Design outcomes

Primary

MeasureTime frameDescription
Expulsion of product of conception24 hours since administration of misoprostolMean duration of expulsion since administration of vaginal misoprostol
Requirement of surgical evacuationbeyond 24 hours since misoprostol administrationSurgical evacuation where complete abortion does not occur

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026